Is VERA a good stock to buy? We came across a bullish thesis on Vera Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VERA. Vera Therapeutics, Inc.'s share was trading at $42.91 as of June 30th.
[caption id="attachment_575381" align="aligncenter" width="750"]Vera Therapeutics (VERA) is positioned as a late-stage biotechnology company with a focused pipeline targeting serious autoimmune and kidney diseases, with its lead asset atacicept forming the core of the investment thesis ahead of...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.